The IMbrave 150 trial further validates the benefit of integrating PD-L1 blockade with anti-angiogenesis, through the administration of atezolizumab (1200 mg) with bevacizumab (15 mg/kg) intravenously every 3 weeks, showcasing significant advancements in HCC management. Here, CD274 is linked to hepatocellular carcinoma.